A deuterated terpyridine diketone compound or a salt thereof, and a preparation method and application thereof
By developing deuterated compounds as p38/MK2 inhibitors, the problem of effectively inhibiting the production of cytokine TNFα in existing technologies has been solved, achieving regulation of inflammatory responses and improved solubility and in vivo pharmacokinetic effects, making them suitable for the treatment of chronic and acute inflammatory diseases.
CN119384410BActive Publication Date: 2026-06-12SHENZHEN SALUBRIS PHARMA CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHENZHEN SALUBRIS PHARMA CO LTD
- Filing Date
- 2023-03-02
- Publication Date
- 2026-06-12
AI Technical Summary
Technical Problem
The lack of effective selective inhibitors of p38/MK2 in existing technologies makes it difficult to effectively regulate inflammation-related diseases, especially the production of the cytokine TNFα.
Method used
A class of deuterated compounds has been developed as p38/MK2 inhibitors, which, through specific structural design, inhibit the production of the cytokine TNFα, thereby regulating inflammation-related diseases.
Benefits of technology
This deuterated compound can significantly inhibit the production of TNFα, improve solubility and in vivo PK effect, and has higher selectivity and safety, making it suitable for the treatment of chronic and acute inflammatory diseases.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure SMS_2 
Figure SMS_5 
Figure SMS_6
Abstract
The application belongs to the technical field of chemical medicines, and relates to a deuterated compound shown in a general formula (I), or a racemate, or an isomer, or a pharmaceutically acceptable salt thereof, which is a p38 / MK2 inhibitor, can inhibit the production of a cytokine TNF alpha, and is used for treating diseases such as arthritis.
Need to check novelty before this filing date? Find Prior Art